TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
European Testing Week 15-22 May 2020
European Testing Week 2020 aims to increase testing efforts & promote awareness on the benefits of hepatitis/HIV testing! More details here.
World Hepatitis Day 28th July 2020!
Keep in mind! World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. Read more
The official kick-off meeting for TherVacB was held online!
Thanks to all TherVacB partners for taking time and for great discussions on how to cure hepatitis B patients!
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
I am so honored and grateful to have been nominated - among all these terrific women!
40 over 40 – Germany's Most Inspiring Women
Happy world women's day to all.
#InternationalWomensDay #Weltfrauentag #IWD2021 #fof21
https://www.curaze.io/femaleonezero/40over40
Thanks for this important post about #hbv and #hdv coinfection basics and recommendations to #healthcare providers! The @TherVacB_EU team is also happy to make use of patient resources and recommendations! #Nohep
New blog post is out! We discuss the basics of #hepatitis B and hepatitis delta #coinfection, list resources for patients, and recommendations for #healthcare providers. Read here: http://www.hepb.org/blog
#hdv #hbv #hepatitisB #nohep
The new blog post is out! We discuss what to expect from the podcast and about exciting existing episodes and upcoming episodes. Read about our brand new podcast, B Heppy, here: http://www.hepb.org/blog
#hbv #hepb #hepatitisB #hepatitis
Main messages of our recent work in JViralHep
👉 Remember to vaccinate against #HBV all patients with liver disease
👉 If cirrhosis, vaccination efficacy ⬇️ (23%)
👉 So, if cirrhosis use double dose x3, check for response and 🔁 again to ⬆️ efficacy (59%)
Efficacy of an accelerated double dose Hepatitis B vaccine regimen in patients with cirrhosis - PubMed
The hepatitis B (HBV) vaccine is recommended in unvaccinated adults with cirrhosis, despite its low efficacy. We aim...
pubmed.ncbi.nlm.nih.gov
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.